Results 31 to 40 of about 24,022 (284)

Comparison of schistosoma mansoni soluble cercarial antigens and soluble egg antigens for serodiagnosing schistosome infections [PDF]

open access: yes, 2011
A Schistosoma mansoni cercarial antigen preparation (cercarial transformation fluid – SmCTF) was evaluated for detection of anti-schistosome antibodies in human sera in 4 collaborating laboratories.
Dawson, E.   +40 more
core   +1 more source

Animal lectins as cell adhesion molecules [PDF]

open access: yes, 1998
Protein-carbohydrate interaction is exploited in cell adhesion mechanisms besides the recognition of peptide motifs. The sugar code thus significantly contributes to the intriguing specificity of cellular selection of binding partners.
Kaltner, H., Stierstorfer, B.
core   +1 more source

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu   +11 more
wiley   +1 more source

Expression analysis of carbohydrate antigens in ductal carcinoma in situ of the breast by lectin histochemistry

open access: yesBMC Cancer, 2008
Background The number of breast cancer patients diagnosed with ductal carcinoma in situ (DCIS) continues to grow. Laboratory and clinical data indicate that DCIS can progress to invasive disease.
Kieber-Emmons Thomas   +3 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

open access: yesHepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou   +13 more
wiley   +1 more source

Tumor-associated Carbohydrate Antigens: Sialyl Lea and T/Tn Antigens in Canine Mammary Tumors [PDF]

open access: yesVeterinary Pathology, 2009
Twenty-eight canine mammary tubulopapillary carcinomas and 14 simple adenomas were studied by immunohistochemistry for the expressions of the tumor-associated carbohydrate antigens. Sialyl Lea was detected in 71.42% of the malignant and 92.84% of the benign tumors.
M, Nowak   +5 more
openaire   +2 more sources

Tumor-Associated Glycans and Immune Surveillance

open access: yesVaccines, 2013
Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that
Anastas Pashov   +2 more
doaj   +1 more source

Niosomes as Biocompatible Scaffolds for the Multivalent Presentation of Tumor-Associated Antigens (TACAs) to the Immune System [PDF]

open access: yes, 2023
Fully synthetic tumor-associated carbohydrate antigen (TACA)-based vaccines are a promising strategy to treat cancer. To overcome the intrinsic low immunogenicity of TACAs, the choice of the antigens' analogues and multivalent presentation have been ...
Lombardi G.   +6 more
core   +1 more source

Colorectal Cancer (CRC): Investigating the Expression of the Suppressor of Fused (SuFu) Gene and Its Relationship with Several Inflammatory Blood-Based Biomarkers

open access: yesBiomedicines, 2023
Background: Suppressor of fused (SuFu) is a tumor-suppressor gene that regulates hedgehog signaling. Its involvement in some malignancies is broadly accepted. However, its association with colorectal cancer (CRC) pathogenesis is not clear.
Tahseen Bilal Rather   +11 more
doaj   +1 more source

State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?

open access: yesCells
Chimeric antigen receptor (CAR)-T cell therapy has proven to be a powerful treatment for hematological malignancies. The situation is very different in the case of solid tumors, for which no CAR-T-based therapy has yet been approved.
Beatriz Amorós-Pérez   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy